Loading
Epidemiologist who led IBIS-I and IBIS-II, proving tamoxifen and anastrozole prevent breast cancer in high-risk women.
Jack Cuzick led the IBIS-I trial (tamoxifen) and IBIS-II (anastrozole) that established chemoprevention of breast cancer in high-risk women, and was the lead statistician of the ATAC trial that made aromatase inhibitors standard adjuvant therapy. He developed the Tyrer-Cuzick risk model and has led HPV-testing studies in cervical screening. His work continues on prevention and risk-based screening.
Shares Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag prevention.
Shares IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years, Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares the tags prevention, breast.
Shares Cervical cancer and the tags prevention, epidemiology.
Shares Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Cervical cancer and the tag prevention.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.